The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

August 31, 2002

Study Completion Date

January 31, 2007

Conditions
Deep Vein ThrombosisPulmonary Embolism
Interventions
DRUG

Low Molecular Weight Heparin (dalteparin)

Trial Locations (13)

TG6 2R7

2E3.32 Walter MacKenzie HSC, Edmonton

V6Z 1Y6

St. Paul's Hospital-Providence Health Care, Vancouver

L8L 2X2

Hamilton Health Sciences- General Site, Hamilton

L8N 3Z5

McMaster University Medical Centre, HSC, Hamilton

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

L8V 1C3

Hamilton Health Sciences-Henderson Site, Hamilton

K1H 8L6

Ottawa Hospital - General Campus, Ottawa

K1Y 4E9

Ottawa Hospital - Civic Campus, Ottawa

M2K 1E1

North York General Hospital-General Site, Toronto

M4C 3E7

Toronto East General Hospital, Toronto

M4N 3M5

Sunnybrook & Women's College Health Sciences Centre, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

H3G 1A4

McGill University Health Centre-Montreal General Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Pfizer

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER